Analgesic Activity of Hexaazaisowurtzitane Derivatives


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Somente assinantes

Resumo

Pronounced analgesic activity of the innovative compound 4-(3,4-dibromthiophencarbonyl)-2,6,8,12-tetraacethyl-2,4,6,8,10,12hexaazatetracyclo[5,5,0,03, 11,05, 9] dodecane (thiowurtzine) was observed in the thermal nociceptive hot plate test and in the acute visceral and somatic deep pain model (acetic acid writhing test). In these experimental models, naloxone-sensitive thiowurtzine-induced analgesia was revealed. The absence of tropism to peripheral opioid receptors in the acetic acid writhing test was demonstrated using naloxone methiodide. Course administration of low-toxic thiowurtzine in effective doses was not associated with ulcerogenic damage to the gastric mucosa in experimental animals.

Sobre autores

S. Krylova

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Autor responsável pela correspondência
Email: krylova5935@gmail.com
Rússia, Tomsk

T. Povet’eva

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: krylova5935@gmail.com
Rússia, Tomsk

E. Zueva

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: krylova5935@gmail.com
Rússia, Tomsk

N. Suslov

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: krylova5935@gmail.com
Rússia, Tomsk

E. Amosova

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: krylova5935@gmail.com
Rússia, Tomsk

T. Razina

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: krylova5935@gmail.com
Rússia, Tomsk

K. Lopatina

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: krylova5935@gmail.com
Rússia, Tomsk

O. Rybalkina

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: krylova5935@gmail.com
Rússia, Tomsk

Yu. Nesterova

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: krylova5935@gmail.com
Rússia, Tomsk

O. Afanas’eva

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: krylova5935@gmail.com
Rússia, Tomsk

E. Kiseleva

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: krylova5935@gmail.com
Rússia, Tomsk

S. Sysolyatin

Institute of Problems of Chemical and Energetic Technologies, Siberian Division of the Russian Academy of Sciences

Email: krylova5935@gmail.com
Rússia, Biysk

D. Kulagina

Institute of Problems of Chemical and Energetic Technologies, Siberian Division of the Russian Academy of Sciences

Email: krylova5935@gmail.com
Rússia, Biysk

V. Zhdanov

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: krylova5935@gmail.com
Rússia, Tomsk


Declaração de direitos autorais © Springer Science+Business Media, LLC, part of Springer Nature, 2019

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies